Stela Filipovic-Sadic, a manager of Research & Development at Asuragen, presented Asuragen’s molecular testing capabilities for FMR1 and Fragile X and showed how new technologies drive progress in the field at the 18^th NFXF Intl Fragile X Conference. Asuragen has been a part of the Fragile X community for years and our tests have been used to help patients, clinicians, and researchers aid in diagnosis, screen potential carriers, stratify risk of Fragile X being passed onto the next generation, and connect patients to new therapies. Contact us to learn more about Fragile X testing. Visit fragilex.org to learn more about the National Fragile X Foundation.